Here in the US, according to news reports issued late on Friday, a federal court in New Jersey invalidated the last remaining patent held by Johnson & Johnson on their formulation of abiraterone acetate, known as Zytiga, and used in the treatment of castration-resistant forms of prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, acatate, access, patent, Zytiga | 6 Comments »
We have known for some time that abiraterone acetate 250 mg, when given with food, appears to have activity that may — in at least some patients — be comparable to the activity of abiraterone acetate 1,000 mg given without food. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, dose, food, Zytiga | 3 Comments »
In December last year we noted an announcement by Bayer that the company was unblinding data from an ongoing clinical trial because of a potential safety issue when radium-223 (Xofigo) was given in combination with abiraterone acetate + prednisone. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, radium-223, safety, Xofigo, Zytiga | Leave a comment »
Late yesterday the US Food and Drug Administration announced the approval of abiraterone acetate (Zytiga) + prednisone for the treatment of men with “high-risk, castration-sensitive”, metastatic prostate cancer. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-sensitive, hormone-sensitive, Zytiga | Leave a comment »
On Wednesday the U.S. Patent Trial and Appeal Board invalidated the last remaining patent on abiraterone acetate (Zytiga), making it possible that generic forms of abiraterone acetate would be available in 2018 (at least in the US). … READ MORE …
Filed under: Uncategorized | Tagged: abiraterone, cost, generic, patent, Zytiga | Leave a comment »
Bayer is to unblind data early from an ongoing randomized clinical trial of radium-223 acetate — on the guidance of the trial’s Independent Data Monitoring Committee (IDMC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, death, facture, radium-223, risk, safety, trial, Xofigo, Zytiga | Leave a comment »
Near the end of last month we had told you that data from the LATITUDE trial and from Arm G of the STAMPEDE trial would be presented at the ASCO annual meeting in Chicago this year. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, outcome, trial, Zytiga | Leave a comment »
It is well understood that drugs can demonstrate better results during the highly controlled, closely monitored setting of a clinical trial than they do in the “real world”. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: azbiraterone, castration-resistant, mCRPC, outcome, Zytiga | 1 Comment »
New guidance in England has expanded coverage of treatment with abiraterone acetate (Zytiga) + prednisone for men with metastatic castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, coverage, NICE, Zytiga | Leave a comment »
According to an article this morning on the PharmaTimes web site, Astellas has convinced the National Institute for Health and Care Excellence (NICE) to recommend coverage of enzalutamide (Xandi) in chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Living with Prostate Cancer, Treatment | Tagged: abiraterone, coverage, enzalutamide, NICE, UK, Xtandi, Zytiga | 3 Comments »
According to a summary statement of opinion issued yesterday by the Committee for Medicinal Products for Human Use (CMPH) of the European Mediciens Agency (EMEA), CMPH is recommending an expanded indication for the clinical use of abiraterone acetate in men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: abiraterone, Europe, indication, Zytiga | 4 Comments »
According to a media release issued today, the UK’s National Institute for Clinical Excellence (NICE) has issued final guidance recommending the use of abiraterone acetate in combination with prednisone or prednisolone as a treatment option for men with metastatic, castration-resistant prostate cancer (mCRPC) that has progressed on or after at least one cycle of treatment with a docetaxel-containing chemotherapy regimen.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, mCRPC, Zytiga | Leave a comment »
In an utterly unsurprising announcement from the UK, the National Institute for Clincial Excellence (NICE) has issued draft guidance in which it refuses to cover the proposed cost of abiraterone actetate. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, cost, NICE, UK, Zytiga | 6 Comments »
THE "NEW" PROSTATE CANCER INFOLINK 